Erasca Inc (ERAS) Stock Price, Quote & News

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of E...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 465 6511

Website: www.erasca.com

Address:

3115 Merryfield Row, Suite 300, San Diego, United States

Alt_Fuel Apr. 24 at 8:29 AM

$VSTM Verastem partner in KRAS ON / OFF " GenFleet Therapeutics " - New 52 Week High on April 24, 2026 $ANL $ELTX $ERAS $RVMD Apr. 23, 2026-- Verastem Oncology $VSTM will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-report-first-quarter-2026-financial-results

1 · Reply

1SwingSensei Apr. 24 at 7:51 AM

$ERAS I turned $1,225 into $73,000 within 5 months & now I'm waiting for another entry.. Read full post https://www.reddit.com/r/swingtrading_options/s/NufLQ8rVw3

0 · Reply

Alt_Fuel Apr. 24 at 7:33 AM

$VSTM annual meeting led by Verastem Oncology GenFleet’s partner. Hong Kong - Jinfang / GenFleet Medicine-B (02595) rose over 3% as two preclinical studies of GFH375 / VS-7375 were selected for breakthrough research abstracts. Zhitong Finance - Apr 23, 2026 GENFLEET-B +11.14% $ERAS $RVMD https://www.moomoo.com/news/post/68806318/hong-kong-stock-movement-jinfang-medicine-b-02595-rose-over?chain_id=bJoStPvEgQD6bO.1kum6kn&futusource=news_web_stockpagenews&global_content=%7B%22promote_id%22%3A13764%2C%22sub_promote_id%22%3A57%2C%22f%22%3A%22mm%2Fstock%2F02595-HK%2Fnews%22%7D&lang=en-us&ns_stock_id=87363929770531&report_id=62142513&report_type=stock&src=43&stock_news_tab=news&level=1&data_ticket=1761581596149365

0 · Reply

CheckingMorons Apr. 23 at 4:39 PM

$ERAS dont be exit liquidity for this company

0 · Reply

STACKD0E Apr. 23 at 4:21 PM

$ERAS

0 · Reply

HeraklesTrading Apr. 23 at 3:56 PM

$ERAS should have +20k watchers here - still under the radar - amazing, how ?!

0 · Reply

HeraklesTrading Apr. 23 at 3:53 PM

$ERAS only a few days left (okay, 3 weeks) !! awaiting monster move - triple down from here?? possible indeed !! moderate risk / ultra high reward play !!

0 · Reply

biolover Apr. 23 at 3:52 PM

$ERAS that is me. Mr thief. It is ok 😂

0 · Reply

biolover Apr. 23 at 3:50 PM

$ERAS reminds me of shorts who lose multiples on their investment 😂 They just go in blindly

1 · Reply

CheckingMorons Apr. 23 at 3:45 PM

$ERAS reminds me a biotech where next reading was fail and dropped to 5 dollars

0 · Reply

Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

Mar 10, 2026, 8:00 AM EDT - 6 weeks ago

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

Mar 5, 2026, 7:01 AM EST - 7 weeks ago

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

Feb 26, 2026, 11:20 AM EST - 2 months ago

Erasca Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 24, 2026, 8:00 AM EST - 2 months ago

Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

Feb 12, 2026, 1:00 PM EST - 2 months ago

Erasca Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 2 months ago

Erasca to Present at Upcoming Conferences in February

Jan 26, 2026, 7:52 AM EST - 3 months ago

Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday?

Jan 23, 2026, 4:01 PM EST - 3 months ago

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 21, 2026, 8:54 PM EST - 3 months ago

Erasca Announces Pricing of Upsized Public Offering of Common Stock

Jan 20, 2026, 4:01 PM EST - 3 months ago

Erasca Announces Proposed Public Offering of $150 Million of Common Stock

Jan 13, 2026, 4:30 PM EST - 3 months ago

Erasca Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 3 months ago

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

Jan 8, 2026, 1:21 PM EST - 3 months ago

What's Going With Cancer Biotech Erasca Stock On Thursday?

Jan 6, 2026, 8:00 AM EST - 3 months ago

Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 10:25 AM EST - 5 months ago

Erasca Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 9:08 AM EST - 5 months ago

Erasca to Present at the 8th Annual Evercore Healthcare Conference

Nov 19, 2025, 5:30 AM EST - 5 months ago

Erasca Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:01 PM EST - 5 months ago

Erasca Reports Third Quarter 2025 Business Updates and Financial Results

Nov 12, 2025, 1:20 PM EST - 5 months ago

Erasca Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 2:00 PM EST - 5 months ago

Erasca Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 8:00 AM EST - 6 months ago

Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

Nov 4, 2025, 8:00 AM EST - 6 months ago

Erasca to Present at Upcoming Conferences in November

Sep 9, 2025, 3:20 PM EDT - 8 months ago

Erasca Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 8:00 AM EDT - 8 months ago

Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Erasca Reports Second Quarter 2025 Business Updates and Financial Results

Jun 10, 2025, 2:40 PM EDT - 11 months ago

Erasca Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 5:30 PM EDT - 11 months ago

Erasca Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 8:00 AM EDT - 11 months ago

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

May 29, 2025, 8:00 AM EDT - 11 months ago

Erasca to Present at Upcoming Investor Conferences in June

May 14, 2025, 5:35 PM EDT - 1 year ago

Erasca Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 4:05 PM EDT - 1 year ago

Erasca Reports First Quarter 2025 Business Updates and Financial Results

May 13, 2025, 8:00 AM EDT - 1 year ago

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

May 7, 2025, 8:00 AM EDT - 1 year ago

Erasca to Present at the Bank of America Securities Health Care Conference

Apr 29, 2025, 4:05 PM EDT - 1 year ago

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Mar 25, 2025, 4:31 PM EDT - 1 year ago

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

Jan 31, 2025, 8:00 AM EST - 1 year ago

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Jan 14, 2025, 12:45 PM EST - 1 year ago

Erasca Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 4, 2024, 11:15 AM EST - 1 year ago

Erasca Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 20, 2024, 7:30 AM EST - 1 year ago

Erasca Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 4:01 PM EST - 1 year ago

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Nov 12, 2024, 2:00 PM EST - 1 year ago

Erasca Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Erasca to Present at Upcoming Investor Conferences

Oct 24, 2024, 8:30 AM EDT - 1 year ago

Erasca Transcript: R&D Update

Sep 18, 2024, 3:40 PM EDT - 1 year ago

Erasca Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 5, 2024, 12:20 PM EDT - 1 year ago

Erasca Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

Jun 12, 2024, 10:40 AM EDT - 2 years ago

Erasca Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 10:30 AM EDT - 2 years ago

Erasca Transcript: Jefferies 2024 Global Healthcare Conference

May 21, 2024, 4:05 PM EDT - 2 years ago

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

May 17, 2024, 8:30 AM EDT - 2 years ago

Erasca Transcript: Status Update

May 16, 2024, 8:02 PM EDT - 2 years ago

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

May 16, 2024, 8:00 PM EDT - 2 years ago

Erasca Announces Pricing of Underwritten Offering of Common Stock

May 15, 2024, 7:20 PM EDT - 2 years ago

Erasca Transcript: BofA Securities 2024 Health Care Conference

May 8, 2024, 4:01 PM EDT - 2 years ago

Erasca Reports First Quarter 2024 Business Updates and Financial Results

May 7, 2024, 8:00 AM EDT - 2 years ago

Erasca to Present at the Bank of America Health Care Conference

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Mar 28, 2024, 8:30 AM EDT - 2 years ago

Erasca Earnings Call Transcript: Q4 2023

Mar 27, 2024, 8:30 PM EDT - 2 years ago

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Mar 27, 2024, 4:01 PM EDT - 2 years ago

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Jan 3, 2024, 8:00 AM EST - 2 years ago

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 8:00 AM EST - 2 years ago

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Nov 28, 2023, 8:00 AM EST - 2 years ago

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Nov 9, 2023, 4:01 PM EST - 2 years ago

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

Nov 8, 2023, 8:00 AM EST - 2 years ago

Erasca to Present at Upcoming Investor Conferences in November

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

Aug 10, 2023, 4:01 PM EDT - 2 years ago

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Jun 22, 2023, 4:01 PM EDT - 3 years ago

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Jun 5, 2023, 4:01 PM EDT - 3 years ago

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

May 31, 2023, 8:00 AM EDT - 3 years ago

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

May 25, 2023, 5:00 PM EDT - 3 years ago

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

Alt_Fuel Apr. 24 at 8:29 AM

1 · Reply

1SwingSensei Apr. 24 at 7:51 AM

$ERAS I turned $1,225 into $73,000 within 5 months & now I'm waiting for another entry.. Read full post https://www.reddit.com/r/swingtrading_options/s/NufLQ8rVw3

0 · Reply

Alt_Fuel Apr. 24 at 7:33 AM

0 · Reply

CheckingMorons Apr. 23 at 4:39 PM

$ERAS dont be exit liquidity for this company

0 · Reply

STACKD0E Apr. 23 at 4:21 PM

$ERAS

0 · Reply

HeraklesTrading Apr. 23 at 3:56 PM

$ERAS should have +20k watchers here - still under the radar - amazing, how ?!

0 · Reply

HeraklesTrading Apr. 23 at 3:53 PM

$ERAS only a few days left (okay, 3 weeks) !! awaiting monster move - triple down from here?? possible indeed !! moderate risk / ultra high reward play !!

0 · Reply

biolover Apr. 23 at 3:52 PM

$ERAS that is me. Mr thief. It is ok 😂

0 · Reply

biolover Apr. 23 at 3:50 PM

$ERAS reminds me of shorts who lose multiples on their investment 😂 They just go in blindly

1 · Reply

CheckingMorons Apr. 23 at 3:45 PM

$ERAS reminds me a biotech where next reading was fail and dropped to 5 dollars

0 · Reply

TrendScout96 Apr. 23 at 12:53 AM

$ERAS is starting to look like one of those biotech setups where the timeline matters more than the chart. From what’s been disclosed, dosing was already at 40mg by Feb, with early signal activity seen at 8mg as far back as January (including multiple responses). The trial only kicked off in June 2025, yet guidance was already pulled forward to mid-May data — that usually doesn’t happen unless internal readouts are meaningfully ahead of schedule. What stands out more is the clinical narrative: a reported lung adenocarcinoma case with a G12V mutation showing rapid functional recovery, including coming off oxygen and returning to work within a week. That kind of response profile suggests a potentially high-potency mechanism (pan-RAS molecular glue approach). In biotech, you don’t ignore early signal + accelerated guidance + strong anecdotal response velocity. The market is still pricing this cautiously, but the setup is clearly shifting from “speculation” to “data anticipation.”

1 · Reply

biolover Apr. 23 at 12:05 AM

$ERAS u don’t sell the most potent pan RAS glue in this market. $MRK Will get it.

0 · Reply

STACKD0E Apr. 22 at 1:25 AM

$ERAS 🙃✨️

0 · Reply

DipinDipout Apr. 21 at 3:23 PM

$ERAS Folks, seeking your input on guesstimates for upcoming SP’s and targets with time lines…🙏 TY

1 · Reply

GrizZley Apr. 20 at 11:39 PM

$ERAS $IBRX …The old saying goes - If you don’t have anything good to say best to not say anything at…

2 · Reply

RobertX916 Apr. 20 at 11:28 PM

$ERAS $IBRX

1 · Reply

Holdyn_Baggins Apr. 20 at 11:20 PM

$ERAS $IBRX

0 · Reply

FrankMolar Apr. 20 at 11:04 PM

$IBRX Barely got a chance to look at the market today. Good to know the dumbass posts didn't stop for this board. $ERAS was up even more and respectful, informative posts without all the pump meme, bad FDA, Dr. P is my buddy drama.

1 · Reply

Floridaorange Apr. 20 at 9:02 PM

$IBRX congrats $ERAS

2 · Reply

NYC100 Apr. 20 at 8:40 PM

$COHU $ERAS $OTLK $SEZL Time to block these fake accounts

0 · Reply

MaverikIT Apr. 20 at 7:12 PM

$ERAS nice $LEGN $KOD $TGTX - LFG

0 · Reply

Alt_Fuel Apr. 20 at 5:42 PM

$VSTM $ANL $ELTX $ERAS $RVMD BTIG Reiterates Buy on Verastem, Maintains $19 Price Target 01:12 PM EDT, April 20, 2026 Updated 27 minutes ago, April 20, 2026 at 1:12 PM EDT 1:12 PM EDT, April 20, 2026 (Benzinga Newswire) BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $19 price target.

1 · Reply

Market Cap	6.98B
Revenue (ttm)	0.00
Net Income (ttm)	-124.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,750,700
Avg Vol	5,391,006
Day's Range	N/A - N/A
Shares Out	310.80M
Stochastic %K	66%
Beta	1.04
Analysts	Strong Sell
Price Target	$17.70